Industry News

Antibe Therapeutics Inc. filed its financial and operating results on Monday, August 29 for the fiscal quarter ended June 30, 2016. The Corporation’ s unaudited fiscal Q1 2017 interim consolidated financial statements and MD&A are available on SEDAR. “We are pleased with the operational progress being made at Citagenix and remain focused on generating growth through new products and international expansion, including in the United States,” said Dan Legault, Antibe’ s..."/>
Antibe Therapeutics Reports Q1 2017 Interim Financial and Operating Results
Masimo announced Sunday at the World Congress of Anaesthesiologists in Hong Kong that it has become the first Global Impact Partner of the World Federation of Societies of Anaesthesiologists. The four-year partnership,“ Safe Anaesthesia– ASAP”, will initially identify one country with poor access to safe anesthesia, and will work toward implementing..."/>
Masimo Announces Four-Year Partnership with World Federation of Societies of Anaesthesiologists (WFSA)
MannKind is making progress on its work to develop an alternative way to distribute the drug epinephrine throughout the body. MannKind is based in Valencia, Calif., and has its manufacturing facility on Casper Street in Danbury. It employs about 150 people in the city."/>
Danbury's MannKind continues work on EpiPen alternative [The Hour, Norwalk, Conn.]
BIOASIS TECHNOLOGIES INC., a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, today announced the publication of a peer-reviewed scientific paper detailing the results of an in-vivo study of the treatment of Metastatic HER2+ Breast Cancer brain tumors in an animal model using BT2111, biOasis's Trastuzumab-Melanotransferrin Conjugate."/>
BiOasis Announces Publication of Scientific Paper -- Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model
Covalon Technologies Ltd., an advanced medical technologies company, announce, pursuant to National Instrument 62? 103, that Goldfarb has acquired 967,650 common shares in the capital of Covalon by exercising 967,650 purchase warrants of Covalon. As a result of the exercised warrants, Goldfarb has increased their holdings to 2,056,655 common shares of Covalon. Goldfarb may from time to time acquire additional securities..."/>
The Goldfarb Corporation Acquires Additional Shares of Covalon Technologies Ltd.
Hemostemix Inc., a clinical-stage autologous cell-therapy company, announced today that it has voided a strategic alliance agreement with Hemostemix Asia, Inc., a private, independent company based in Taipei, Taiwan. The agreement covered a manufacturing and commercial license of the Hemostemix ACP-01 technology to HEMA for treating critical limb ischemia patients in Taiwan, China, and South Korea. According to the agreement, HEMA was supposed to..."/>
Hemostemix Voids Taiwanese Agreement
Rigel Pharmaceuticals, Inc. announced that the company will announce results of the first of two FIT Phase 3 studies of fostamatinib for patients with immune thrombocytopenia, at 7:00 a.m. Eastern Time on Tuesday, August 30, 2016. The company will also host a conference call at 8:00 a.m. Eastern Time to discuss the Phase 3 study results. Participants can access the live conference call by dialing 855-892-1489 or 720-634-2939..."/>
Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016
Covalon Technologies Ltd., an advanced medical technologies company, today announced that all of the holders of the share purchase warrants subscribed in the private placement of August 2013 that would otherwise expire on August 30, 2016, have exercised their warrants, representing a total number of 4,838,250 Common Shares of the Corporation, for a total exercise price of $749,929. After the exercise of warrants, the Company will have a total of..."/>
Covalon Announces Exercise of Warrants
Nightingale Informatix Corporation announced today it has filed its financial results for its fiscal first quarter ended June 30, 2016. Additional information concerning the Company, including its condensed consolidated financial statements and its Management's Discussion and Analysis of Financial Condition and Results of Operations for the quarter ended June 30, 2016 can be found at www.sedar.com. The Company is reporting substantially..."/>
Nightingale Files First Quarter F17 Results
Phibro Animal Health Corporation today announced its financial results for its fourth quarter and fiscal year ended June 30, 2016. It also provided guidance for its fiscal year ending June 30, 2017.. Highlights for the June 2016 quarter Net sales of $189 million, an increase of 2% Net income of $15 million, an increase of 46% Diluted EPS of $0.38, an increase of 46% Adjusted EBITDA of $28 million, an increase of 4% Adjusted diluted EPS of $0.40, a decrease of 9%..."/>
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year
Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted orphan drug designation to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for the treatment of graft-versus-host disease. Alexion is currently investigating ALXN1007 in patients with acute GVHD of the lower gastrointestinal tract, a severe and life-threatening rare autoimmune disease that can occur as a complication..."/>
European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
VIVUS, Inc. and Auxilium Pharmaceuticals, Inc., a subsidiary of Endo International plc, today announced an extension of the termination date of the license agreement between Auxilium and VIVUS for STENDRA ® U.S. and Canadian commercial rights through September 30, 2016.. "We have been working closely with Auxilium to ensure a smooth transition of STENDRA back to VIVUS," said Seth H. Z. Fischer, VIVUS Chief Executive Officer. " Through this process, we have..."/>
VIVUS Extends Return Date of STENDRA Commercial Rights
Castlight Health, Inc., a leading health benefits platform provider, today announced that technology industry leader Kenny Van Zant has joined its Board of Directors. Bryan Roberts, PhD, co-founder of Castlight and general partner at Venrock, remains Castlight's Chairman of the Board. Most recently, Kenny Van Zant was the Head of Business at Asana, the creator of cloud-based SaaS project management tools, where he led all business functions, including..."/>
Technology Industry Leader Kenny Van Zant Joins Castlight Health Board of Directors
WellCare Health Plans, Inc. announced today that Mark Leenay, M.D., has been named chief medical director, care model, effective today. Leenay will provide strategic leadership for the company's model of care and care management programs to increase the efficiencies and effectiveness of clinical outcomes. He will also work closely with the executive team, the chief medical directors of utilization management and quality, the local markets and..."/>
WellCare Names Dr. Mark Leenay Chief Medical Director
Catalent's proprietary OptiShell™ softgel technology has been selected for use in OPKO Health's NDA for RAYALDEE ® and has been approved by the U.S. FDA Announced the launch of our FastChain™ service, for greater speed, flexibility and efficiency in the management and distribution of global..."/>
Catalent, Inc. Reports Fourth Quarter and Fiscal Year 2016 Results
HealthEquity, Inc., one of the largest HSA non-bank custodians, today announced that its Board of Directors has appointed Adrian T. Dillon to the Company’ s Board of Directors and to its Audit and Risk Committee, effective September 1, 2016. Dillon brings with him more than 35 years of financial leadership and experience with business operations, corporate development and consumer financial technology.. “We are delighted that Adrian will be joining our..."/>
HealthEquity Appoints New Director to the Board
Haemonetics Corporation announced that Gerry Gould, Vice President– Investor Relations, will present at The Baird 2016 Global Healthcare Conference in New York on Thursday, September 8, 2016 at 3:10pm Eastern time. The public may access Mr. Gould's presentation live via webcast at http://wsw.com/webcast/baird46/hae."/>
Haemonetics to Present at The Baird 2016 Global Healthcare Conference
Teladoc, Inc., the nation’ s first and largest telehealth provider, announced that Henry DePhillips, MD, FACEP, Teladoc chief medical officer, will participate in a panel discussion on virtual, on-demand health care at the third annual Connected Health Summit: Engaging Consumers in San Diego, Calif on August 30– September 1, 2016.. DePhilips’ panel,“ Bring Doctors to Your Home: Virtually and In Person,” will take place on Thursday, September 1, from 1:30 p.m.– 2:30 p.m. at..."/>
Teladoc Chief Medical Officer Dr. Henry DePhillips to Participate in Third Annual Connected Health Summit
Teva Pharmaceutical Industries Ltd. plans to overview the future prospects of the Teva Generics business on 9 September, following the close of the company's Actavis generics deal, the company said on Monday. On that date, Teva will host a conference call and live webcast along with a slide presentation. The presentation will focus on strategy, commercial, portfolio and R/D capabilities and will include an overview of specific pipeline opportunities in..."/>
Teva to Overview Future of Generics Business Following Actavis Deal
HealthSouth Corp. and Tidelands Health have formed a joint venture to own and operate Tidelands' existing inpatient rehabilitation hospital, the companies said on Monday. The hospital is located inMurrells Inlet, South Carolina, on the campus of Tidelands Waccamaw Community Hospital. This joint venture expects to operate 29 inpatient rehabilitation beds at this location."/>
HealthSouth, Tidelands Health Form JV Operate Inpatient Rehabilitation Hospitals
Neurocrine Biosciences, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for once-daily dosing of valbenazine in treating tardive dyskinesia. "This is an important milestone in the development of valbenazine for the treatment of tardive dyskinesia, a serious disease for which there is no FDA approved pharmaceutical treatment," said Kevin C. Gorman, President and Chief Executive Officer..."/>
Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary659 Articles
Information Technology597 Articles
Financials509 Articles
Health Care352 Articles
Industrials352 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.